Pathway
|
Osteoarthritis
|
|
Oncogene Induced Cellular Senescence
|
|
MTHFR Activity Regulation
|
|
DNA Persistent Repair Inhibits mTOR Signaling
|
|
mTOR Signaling Activation by Fatty Acids and Glucose
|
|
mTOR Signaling Activation by Amino Acids
|
|
mTOR Signaling
|
|
mTOR Signaling Hyperfunction
|
|
Insulin Influence on Protein Synthesis
|
|
Insulin Influence on Glycogenesis
|
|
Insulin Influence on Lipogenesis
|
|
Dopamine Receptors Signaling
|
|
Serotonin Receptors Signaling
|
|
Thyroid Hormones Common non-Genomic Effects in Hyperthyroidism
|
|
Insulin Signaling
|
|
Thrombopoietin Receptors Signaling in Platelet Maturation
|
|
LH and FSH Signaling and Steroidogenesis
|
|
Toll-like Receptors Act through MYD88-TIRAP Signaling
|
|
T-Cell Dependent B-Cell Activation
|
|
T-Cell Independent B-Cell Activation
|
|
Natural Killer Cell Activation through C-Type Lectin-like Receptors
|
|
Natural Killer Cell Activation through ITAM-Containing Receptors
|
|
Natural Killer Cell Activation through ITSM-Containing Receptors
|
|
T-Cell Maturation (Hypothesis)
|
|
Peripheral T-Cell Tolerance
|
|
T-Cell Positive Selection and Neglect Induced Death
|
|
T-Cell Central Tolerance
|
|
CD8+ T-Cell Activation
|
|
Th1-Cell Differentiation
|
|
Treg-Cell Differentiation
|
|
Th2-Cell Differentiation
|
|
T-Cell Receptor Signaling
|
|
Th17-Cell Differentiation
|
|
AHR Signaling in Tr1 Cells Function
|
|
CXC Chemokine Receptor Signaling
|
|
CC Chemokine Receptor Signaling
|
|
Plasmin Effects in Inflammation
|
|
TAM Receptors in Platelet Aggregation
|
|
Platelet Activation via Adhesion Molecules
|
|
Scavenger Receptors in Platelet Aggregation
|
|
Proplatelet Maturation
|
|
Bradykinin Effects in Inflammation
|
|
Platelet Activation via GPCR Signaling
|
|
Toll-like Receptors in Sterile Inflammation
|
|
Toll-like Receptor Independent Sterile Inflammation
|
|
Lipoxin A4/FPR2-Related Neutrophil Depression
|
|
Eicosanoids in Myeloid Cell Activation
|
|
Histamine Receptor H3 Signaling in Neurons
|
|
Neutrophil Activation via LTB4/Polyisoprenyl Phosphate Signaling
|
|
Basophil Activation
|
|
Eosinophil Survival by Cytokine Signaling
|
|
Eosinophil Activation
|
|
Mast-Cell Activation via IgE Signaling
|
|
Mast-Cell Activation without Degranulation through CYSLTR1/CYSLTR2 Signaling
|
|
Mast-Cell Activation without Degranulation
|
|
Mast-Cell Activation without Degranulation through KIT/F2R Signaling
|
|
Mast-Cells De Novo Synthesized Mediators via IgE Independent Signaling
|
|
CD16/CD14 Proinflammatory Monocyte Activation
|
|
Neutrophil Activation via FCGR3B
|
|
Neutrophil Degranulation via FPR1 Signaling
|
|
Neutrophil Chemotaxis
|
|
Neutrophil Activation via Adherence on Endothelial Cells
|
|
VEGFA/NOTCH1/WNT Cross-talk in Blood Vessel Sprouting and Branching in Cancer
|
|
Vascular Endothelial Cell Activation by Cytokines
|
|
Vascular Endothelial Cell Activation by Blood Coagulation Factors
|
|
Vascular Endothelial Cell Activation by Growth Factors
|
|
Vascular Endothelial Cell Permeability Activation
|
|
Lipogenesis Regulation in Adipocyte
|
|
Synaptic Potentiation by PKMZ in LTP Maintenance - Active State
|
|
Potassium Flux Regulation
|
|
GFs/TNF -> Ion Channels
|
|
Nociception Expression Targets Signaling
|
|
Sodium Flux Regulation
|
|
Vascular Motility
|
|
Ca2+ Flux Regulation
|
|
NPY1R -> CRH/POMC Production
|
|
NTSR1 Expression Targets
|
|
BDKRB1/2 -> Vasodilation
|
|
BDKRB1/2 -> Interleukins Production
|
|
CNR1/2 -> Membrane Transport
|
|
CNR1/2 -> IL1B/2/4/6/10 Production
|
|
DRD2 Expression Targets
|
|
DRD2 -> TRPC1 Transcription
|
|
DRD2/4 -> Membrane Transport
|
|
GALR1/2/3 -> POMC/NPY Production
|
|
CHRM1 -> IL2 Production
|
|
CHRM1/2/3/5 -> Ion Channels
|
|
PTGER2/3 -> Vascular Motility
|
|
HTR1 -> IL6 Production
|
|
HTR5 -> TNF Production
|
|
HTR1 -> Membrane Transport
|
|
TACR1 -> TNF/IL6/IL8 Production
|
|
Leptin -> NO Production/Vasodilation
|
|
NTRK1/2/3 -> Acetylcholine Production
|
|
T-lymphoid precursor cell -> CD8+ Naive T-cell Surface Expression Markers
|
|
G0/G1 Phase Transition
|
|
RAGE/AGER and S100 Proteins in Cardiovascular Injury
|
|
Th1-Cells Activation and Proliferation in Atherosclerosis
|
|
Dilated Cardiomyopathy
|
|
Endothelin Signaling in Arterial Hypertension
|
|
Arterial Hypertension
|
|
Endothelial Cell Dysfunction in Arterial Hypertension
|
|
Smooth Muscle Cell Dysfunction in Arterial Hypertension
|
|
TRPM4/6/7/8 Signaling in Arterial Hypertension (Hypothesis)
|
|
Smooth Muscle Cell Dysfunction in Pulmonary Hypertension
|
|
Myocardial Remodeling
|
|
Myocardial Infarction
|
|
Proteins Involved in Myocardial Ischemia
|
|
Preconditioning Ischemia
|
|
Lymphocyte Mediated Myocardial Injury in Myocarditis
|
|
Myocarditis, Acute Viral Overiew
|
|
Vascular Reactivity in Raynaud Disease
|
|
NO Synthesis in Early Vasospasm
|
|
Neurons Necrosis Caused by Energy Deficiency
|
|
Contraction Due Vasospasm
|
|
Hyperseborrhea in Acne Vulgaris
|
|
Androgen Induced Sebocyte Hyperfunction
|
|
Androgens in Sebocyte Maturation
|
|
Atopic Dermatitis Onset
|
|
Cell Cycle Dysregulation in Melanoma
|
|
Melanoma
|
|
Apoptosis Block in Melanoma Cell
|
|
Dedifferentiation and Metastatic Progression in Melanoma
|
|
MITF as a Regulator of Melanoma Cell Development
|
|
Proteins Involved in Melanoma
|
|
IFN-gamma/TNF-alpha Mediated Cell Proliferation in Psoriasis
|
|
IL22 Induces Keratinocyte Proliferation in Psoriasis
|
|
Dendritic Cells Function in Psoriasis
|
|
Th0-Cell Aberrant Activation in Systemic Lupus Erythematosus
|
|
Th1-Cell Function in Systemic Lupus Erythematosus
|
|
B-Cell Activation in Systemic Lupus Erythematosus
|
|
Th2-Cell Function in Systemic Lupus Erythematosus
|
|
Acute Cytotoxic CD8+T-Cell Response against Melanocytes
|
|
Vitiligo
|
|
T-Cell Cytotoxic Response against Melanocytes in Vitiligo
|
|
Apoptosis of Melanocyte in Vitiligo
|
|
Humoral Immunity in Vitiligo
|
|
Treg-Cell Function in Diabetes Mellitus Type 1
|
|
Natural Killer T-Cell Roles in Diabetes Mellitus Type 1
|
|
Toll-like Receptors in beta-Cell
|
|
Macrophage Function in Diabetes Mellitus Type 1
|
|
Treg-Cell Activation in Diabetes Mellitus
|
|
Donohue Syndrome Progression (Hypothesis)
|
|
Advanced Glycation End Products Pathway in Diabetic Microangiopathy
|
|
Peripheral Tissue Microangiopathy
|
|
Tubular Cell Dysfunction in Progressive Diabetic Nephropathy
|
|
Podocyte Dysfunction in Diabetic Nephropathy
|
|
Endothelial Cell Dysfunction in Early Diabetic Nephropathy
|
|
Mesangial Cell Dysfunction in Diabetic Nephropathy
|
|
Microangiopathy in Diabetic Neuropathy
|
|
Proliferative Diabetic Retinopathy
|
|
Adipokines and Cytokines in Insulin Resistance in Skeletal Muscles
|
|
AGE Related Insulin Resistance in Skeletal Muscles
|
|
Gluconeogenesis Impairment in non-Alcoholic Fatty Liver Disease
|
|
PNPLA3 in non-Alcoholic Fatty Liver Disease
|
|
Lipid Metabolism Impairement in non-Alcoholic Fatty Liver Disease
|
|
Leptin in Insulin Synthesis and Secretion
|
|
beta-Cell Destruction through Cytokines in Diabetes Mellitus
|
|
beta-Cell Mass Regulation
|
|
beta-Cell Function Inhibition by Ciclosporine and Tacrolimus (Rodent Model)
|
|
FOXO1 and SREBP-1C Role in beta-Cell Suppression (Rodent Model)
|
|
RET1 Mutation in Hyperparathyroidism
|
|
Bone Remodeling in Hyperthyroidism
|
|
Cardiovascular Effects in Hyperthyroidism
|
|
Thyroid Dysfunction
|
|
Graves Ophthalmopathy
|
|
Immune System Activation in Hyperthyroidism
|
|
Hypothyroidism, Secondary (Central)
|
|
Thyroid Stimulating Hormone (TSH) Resistance in Congenital Hypothyroidism
|
|
Overt Hypothyroidism, Primary
|
|
Thyroid Stimulating Hormone (TSH) Secretion in Overt Hypothyroidism
|
|
Thymic Follicular Hyperplasia
|
|
Adipocyte Hypertrophy and Hyperplasia
|
|
CD4+T-Cell Response in Celiac Disease
|
|
Enterocyte Mediated Mucosal Damage in Celiac Disease
|
|
Metastatic Colorectal Cancer
|
|
GUCY2C Signaling in Colorectal Cancer
|
|
OipA Signaling in Helicobacter Pylori Infection
|
|
Peutz-Jeghers Syndrome
|
|
Dendritic Cell Function in Ulcerative Colitis
|
|
Nicotine anti-Inflammatory Effect in Ulcerative Colitis
|
|
Th2-Cell Function in Ulcerative Colitis
|
|
T-Cell Cytotoxic Response in Ulcerative Colitis
|
|
FLT3/KIT/MLL Signaling in Leukemia
|
|
Apoptosis Block in Acute Myeloid Leukemia Cell
|
|
RARA Signaling in Acute Myeloid Leukemia (M3)
|
|
Acute Myeloid Leukemia
|
|
Antiphospholipid Antibodies in Platelets and Coagulation Cascade
|
|
B-Cell Acute Lymphoblastic Leukemia
|
|
B-Cell Chronic Lymphocytic Leukemia
|
|
Chronic Myeloid Leukemia
|
|
Diffuse Large-B-Cell Lymphoma
|
|
Diffuse Large-B-Cell Lymphoma ABC Subtype
|
|
Lymphoma, GCB Subtype
|
|
Follicular Lymphoma
|
|
Hodgkin Lymphoma
|
|
Mantle Cell Lymphoma
|
|
mTOR/NF-kB/BCR Signaling Disregulation in Mantle Cell Lymphoma
|
|
Hedgehog Signaling in Mantle Cell Lymphoma
|
|
Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
|
|
Osteoclast Activation in Multiple Myeloma
|
|
IL6/IGF1/VEGFA Signaling in Multiple Myeloma
|
|
Multiple Myeloma
|
|
Platelet and Coagulation Cascade Activation by Antiphospholipid Antibodies
|
|
T-Cell Acute Lymphoblastic Leukemia
|
|
Hepatocellular Carcinoma
|
|
Growth Factor Signaling in Hepatocellular Carcinoma
|
|
Pancreatic Ductal Carcinoma
|
|
Growth Factor Signaling in Pancreatic Neoplasms
|
|
Pancreatic Neuroendocrine Tumors
|
|
STK11 Signaling in Pancreatic Neoplasms
|
|
Il17 Signaling Related Neutrophilia in Asthma
|
|
Airway Smooth Muscle Cell High Rate Proliferation
|
|
IgE Induces Airway Smooth Muscle Cell Proliferation
|
|
Goblet-Cell Exocytosis in Asthma
|
|
Goblet-Cell Related Mucus Secretion in Asthma
|
|
Neutrophil Degranulation via FPR1/IL8
|
|
Basophil Activation in Asthma
|
|
Mast-Cell Activation in Asthma
|
|
Mast-Cell Related Chemokines Signaling in Asthma
|
|
B-Cell Mediated IgE Production in Asthma
|
|
Th17-Cell Differentiation in Asthma
|
|
Th2-Cell Response in Asthma
|
|
Ovulation Block
|
|
SHBG and IGFBP1 Synthesis Decline in Polycystic Ovary Syndrome
|
|
Polycystic Ovary Syndrome
|
|
FSH Action in Polycystic Ovary Syndrome
|
|
Dendritic Cell Dysfunction in Psoriatic Arthritis
|
|
Th17-Cell and Th1 Immune Responsein Psoriatic Arthritis
|
|
Keratinocyte Activation in Psoriatic Arthritis
|
|
B-Cells Function in Systemic Scleroderma
|
|
Th2-Cells Function in Systemic Scleroderma
|
|
CD4+ T-Cell Function Decline in HIV
|
|
Macrophage Survival through CCR5 and CXCR4 Mediated Signaling
|
|
Toll-like Receptors (TLR) in Periodontitis
|
|
Diabetes Induced Periodontitis
|
|
Estrogen Effects on Pregnancy Gingivitis
|
|
IL1 Receptor Antagonist (IL1RN) Deficiency (DIRA)
|
|
Mevalonate Kinase Deficiency
|
|
Blau Syndrome
|
|
Familial Cold Autoinflammatory Syndrome 2
|
|
Hereditary Hemorrhagic Telangiectasia
|
|
Cowden Syndrome
|
|
Glutamate Toxiicity Effects on Striatum Medium Spiny Neurons in Hantington's Disease
|
|
IL6 and Insulin Resistance in Muscular Dystrophies
|
|
Ca2+ Overload in Muscular Dystrophies
|
|
Muscular Dystrophies
|
|
Dystrophin Glycoprotein Complex Signaling in Muscular Dystrophies
|
|
IGF1 Role in Muscle Hypertrophy
|
|
Myostatin-IGF1 Crosstalk in Skeletal Muscles in Muscular Dystrophies
|
|
Osteoblast Function Decline in Osteoporosis
|
|
BDNF Upregulation Triggered by Seizures
|
|
Ketogenic Diet Mechanism (Hypothesis)
|
|
Blood-Brain Barrier Disruption in Epileptiform Disorders
|
|
mTOR Hyperactivation after Status Epilepticus
|
|
Glioblastoma, Primary
|
|
Glioblastoma, Secondary
|
|
Astrocytoma
|
|
Glioma Invasion Signaling
|
|
Glioma Stem Cell Program Activation
|
|
Ependymoma
|
|
Medulloblastoma
|
|
Vascular Endothelial Cell Vasodilation in Brain
|
|
Dopamine Action in CSD Progression
|
|
Postsynaptic Neuron Activation
|
|
nNOS (NOS1) and iNOS (NOS2) Activation via Glutamate
|
|
Growth Factor Signaling in Neuroblastoma
|
|
Neuroblastoma
|
|
ALK Associated Neuroblastoma
|
|
Glutamate Role in Parkinson's Disease
|
|
Glutamate Mediated Excitotoxicity in Amyotrophic Lateral Sclerosis
|
|
Microglia and Motor Neuron Interaction Dysregulation
|
|
MIR155 Role in Th17-Cell in Multiple Sclerosis
|
|
Brain Cell Necrosis in Vascular Dementia
|
|
Proteins Involved in Breast Cancer Related to ESR1 Signaling Pathway
|
|
Proteins Involved in Breast Cancer Related to ERBB2/VEGFR/Akt Signaling Pathway
|
|
ERBB/VEGFR/Akt Signaling in Breast Cancer
|
|
IGF1R/AKT Signaling in Breast Cancer
|
|
ESR1/ERBB Positive Luminal Breast Cancer
|
|
Proteins Involved in Breast Cancer Related to IGF1R/Akt Signaling Pathway
|
|
Breast Cancer
|
|
ESR1 Signaling in Breast Cancer
|
|
Endometrial Cancer
|
|
Endometrioid Endometrial Cancer
|
|
Clear Cell Endometrial Cancer and Papillary Serous Endometrial Cancer
|
|
Angiogenesis in Endometriosis
|
|
Coagulation Factors and PAR1/2 Receptors (F2R/F2RL1) in Endometriosis
|
|
Endometrioid Ovarian Carcinoma
|
|
Clear Cell Ovarian Carcinoma
|
|
High-Grade Serous Ovarian Carcinoma
|
|
Low-Grade Serous Ovarian Carcinoma
|
|
Ovarian Cancer
|
|
Mucinous Ovarian Carcinoma
|
|
LH and FSH Signaling Impairment in Primary Ovarian Insufficiency
|
|
FOXO3 and PTEN Inactivation in Premature Ovarian Failure (Mouse Model)
|
|
MIF Role in Cholesteatoma
|
|
EGF/cyclinD1 Signaling in Acquired Middle Ear Cholesteatoma
|
|
HMGB1/RAGE Signaling in Middle Ear Cholesteatoma
|
|
Cholesteatoma
|
|
HPV E5 Regulates EDNRA and EGFR Signaling Pathway in Keratinocytes
|
|
Androgen Receptor/Akt Signaling
|
|
Prostate Cancer
|
|
Androgen Receptor/SGK1 Signaling
|
|
Steroids Induced Cataract
|
|
VEGFA in Neovascular Glaucoma
|
|
Glutamate Mediated Excitotoxicity in Glaucoma
|
|
Neurotrophic Factor Deprivation in Retinal Ganglion Cell Death
|
|
Immune System Role in Otitis Media
|
|
Alveolar Macrophages Dysfunction in COPD
|
|
T-Cell Cytotoxic Activation
|
|
Alveolar Epithelial Cell Dysfunction in COPD
|
|
Polycystins Mutation Effects in Cystic Kidney Disease
|
|
Penile Detumescense Augmentation Mechanisms
|
|
Advanced Glycation End Products in Diabetes or Age Related Erectile Dysfunction
|
|
Plasmin Role in Glomerulonephritis
|
|
Endothelial Cell Dysfunction in Glomerulonephritis
|
|
Ammonia Effects on Brain Cells
|
|
CD157/ITGB2 Signaling in Myeloid Cell
|
|
CD38/CD3 -> JUN/FOS/NF-kB Signaling in T-cell Proliferation
|
|
CD38/CD19 -> JUN/FOS/NF-kB Signaling in B-cell Proliferation
|
|
S100P Expression Target
|
|
HMGB1 Expression Targets
|
|
TTR Expression Targets
|
|
S100B Expression Targets
|
|
ANGPT1 -> CREB/CREBBP Expression Targets
|
|
ANGPT2 -> AP-1/CREBBP/MYC Expression Targets
|
|
AREG -> NFATC Expression Target
|
|
AREG -> CREB/CREBBP Expression Targets
|
|
AREG -> NCOR2 Expression Targets
|
|
AREG -> HIF1A Expression Targets
|
|
AREG -> AP-1 Expression Targets
|
|
AREG -> FOXO3A Expression Target
|
|
Noradrenaline/Gs Expression Targets
|
|
Epinephrine/Gs Expression Targets
|
|
Acetylcholine Expression Targets
|
|
Dopamine/Gi Expression Targets
|
|
Aryl Hydrocarbon Receptor Genomic and non-Genomic Signaling
|
|
BTC -> NFATC Expression Targets
|
|
BTC -> AP-1/ATF/CREB Expression Targets
|
|
BTC -> EP300/ETS/ETV/SP1 Expression Targets
|
|
AGTR1 -> ARRB1/ARRB2 Signaling
|
|
Hedgehog Family -> ARRB1/ARRB2 Canonical Signaling
|
|
CD19 Expression Targets
|
|
CD81 -> AP-1 Expression Targets
|
|
CD247 Expression Targets
|
|
FCGR3A Expression Targets
|
|
CD19/CR2 Expression Targets
|
|
Tamoxifen Induced Endometrial Cancer
|
|
Dexamethasone Induced Diabetes
|
|
Doxorubicin Induced Cardiotoxicity
|
|
Ritonavir Induced Diabetes
|
|
Clozapine Induced Granulocytopenia
|
|
EGF -> HIF1A Expression Targets
|
|
EGF -> AP-1/ATF Expression Targets
|
|
EGF -> CREB/CREBBP/ELK/SRF/MYC Expression Targets
|
|
EGF -> MEF/MYOD/NFATC Expression Targets
|
|
EGF -> FOXO3A Expression Targets
|
|
EGF -> TP53 Expression Targets
|
|
EGF -> NCOR2 Expression Target
|
|
EGFR -> NCOR2 Signaling
|
|
EGFR/ERBB3 -> MEF/MYOD/NFATC/MYOG Signaling
|
|
EGFR/ERBB2 -> TP53 Signaling
|
|
ERBB2/3 -> EP300/ETS/ETV/SP1 Signaling
|
|
EGFR/ERBB2 -> HIF1A Signaling
|
|
EGFR -> AP-1/ATF2 Signaling
|
|
EGFR -> AP-1/CREB/ELK/SRF/MYC Signaling
|
|
EREG -> CREB Expression Target
|
|
EREG -> EP300/SP1 Expression Targets
|
|
EREG -> FOXO3A Expression Target
|
|
EREG -> HIF1A Expression Target
|
|
EREG -> AP-1/ATF Expression Targets
|
|
Erythropoietin -> FOXO3A Expression Targets
|
|
Erythropoietin -> NF-kB Expression Targets
|
|
Erythropoietin -> AP-1/MYC/CREB Expression Targets
|
|
Erythropoietin -> ELK/SRF Expression Targets
|
|
PECAM1 Expression Targets
|
|
F2 -> AP-1/CREB/ELK/SRF/SP1 Expression Targets
|
|
F2 -> STAT1/NF-kB Expression Targets
|
|
PLG -> AP-1/CREB/ELK/SRF/SP1 Expression Targets
|
|
PLG -> STAT1/NF-kB Expression Targets
|
|
FGF9 -> AP-1/CREB/MYC Expression Targets
|
|
FGF10 -> AP-1/CREB/CREBBP/MYC Expression Targets
|
|
FGF2 -> FOXO3A Expression Targets
|
|
FGF1 -> AP-1/CREB/ELK/SRF/MYC Expression Targets
|
|
FGF1 -> NCOR2 Expression Target
|
|
FGF7 -> FOXO3A Expression Target
|
|
FGF8 -> AP-1/CREB/MYC Expression Targets
|
|
FGF18 -> AP-1/CREB Expression Targets
|
|
FGF23 -> NCOR2 Expression Targets
|
|
FGF10 -> FOXO3A Expression Target
|
|
FGF2 -> NCOR2 Expression Targets
|
|
FGF4 -> AP-1/MYC Expression Targets
|
|
FGF7 -> AP-1/CREB/CREBBP/MYC Expression Targets
|
|
FGF2 -> AP-1/CREB/CREBBP/ELK/SRF/MYC Expression Targets
|
|
FGFR -> AP-1/CREB/CREBBP/ELK/SRF/MYC Signaling
|
|
FSHR Expression Targets
|
|
GH1/GHR -> NF-kB/ELK/SRF/MYC Expression Targets
|
|
CSH1/GHR Expression Targets
|
|
HBEGF -> FOXO3A Expression Target
|
|
HBEGF -> AP-1/ATF Expression Targets
|
|
HBEGF -> TP53 Expression Targets
|
|
HBEGF -> EP300/ETS/ETV/SP1 Expression Targets
|
|
HBEGF -> HIF1A Expression Targets
|
|
HBEGF -> MEF/MYOD Expression Target
|
|
HBEGF -> CREB/MYC Expression Targets
|
|
HGF -> FOXO3A Expression Targets
|
|
HGF -> AP-1/CREB/ELK/SRF/MYC Expression Targets
|
|
HGFR -> FOXO3A Signaling
|
|
HGFR -> AP-1/CREB/MYC Signaling
|
|
TAM Receptor Signaling Activation in Cancer
|
|
PI3K/AKT/MTOR Signaling Activation in Cancer
|
|
G0/G1 Cell Cycle Phase Transition Activation in Cancer
|
|
RAS/RAF/MAPK Signaling Activation in Cancer
|
|
N2 Neutrophils in Tumor-Promoting Inflammation and Tumor Progression
|
|
RAS/RAF/MAPK Signaling Activation by Blocking of Tumor Suppressors
|
|
TGFB Signaling activation by Blocking of Tumor Suppressors
|
|
PI3K/AKT/MTOR Signaling Activation by Blocking of Tumor Suppressors
|
|
Hypoxia-Induced Cell Death Evasion in Cancer
|
|
HIF1A in Vasculogenic Mimicry of Cancer
|
|
VEGFA Dependent Angiogenesis in Cancer
|
|
ANGPT/TEK Maintains Endothelial Cell Quiescence in Cancer
|
|
Inhibition of THBS1 Activates Angiogenesis in Cancer
|
|
VEGF Independent Angiogenesis in Cancer
|
|
Proteins with Altered Expression in Cancer Metastases
|
|
Epithelial to Mesenchymal Transition in Cancer: Overview
|
|
MTOR/TORC in Cancer Cell Motility and Invasion
|
|
Hyaluronic Acid, CD44 and HMMR in Cancer Cell Invasion and Survival
|
|
CDH2 Activation Promotes Cancer Cell Migration and Survival
|
|
TGFB Family in Epithelial to Mesenchymal Transition in Cancer
|
|
Invadopodia Formation in Cancer Cells
|
|
Skeletal Muscle Wasting in Cancer Cachexia
|
|
Metabolic Effects of Oncogenes and Tumor Suppressor in Cancer Cells
|
|
Lipogenesis/Lipolysis Activation in Cancer Cells and Cancer-Associated Adipocytes
|
|
Treg Cells Promote Immunosuppression in Cancer Immune Escape
|
|
IDO1 in Cancer Immune Escape
|
|
Effector T-cell Inactivation in Cancer Immune Escape
|
|
IGF1 -> MEF/MYOD/MYOG Expression Targets
|
|
IGF1 -> CEBPA/FOXO1A Expression Targets
|
|
IGF2 -> CEBPA/FOXO1A Expression Targets
|
|
IGF2/MEF/MYOD Expression Targets
|
|
Insulin -> CEBPA/CTNNB/FOXA/FOXO Expression Targets
|
|
Insulin -> MEF/MYOD Expression Targets
|
|
Insulin -> ELK/SRF/HIF1A/MYC/SREBF Expression Targets
|
|
CD19 -> NF-kB Signaling
|
|
AGER -> NF-kB Signaling
|
|
ICAM2 -> CTNNB/FOXO/STAT3 Signaling
|
|
FcIgER -> ELK-SRF Signaling
|
|
InsulinR -> CTNNB/FOXA/FOXO Signaling
|
|
InsulinR -> ELK/SRF/SREBF Signaling
|
|
IGF1R -> CEBPA/FOXO1A Signaling
|
|
IGF1R -> MEF/MYOD/MYOG Signaling
|
|
FibronectinR -> CTNNB Signaling
|
|
FibronectinR -> NF-kB Signaling
|
|
FibronectinR -> AP-1/ELK/SRF/SREBF Signaling
|
|
MacrophageR -> CEBPB -> NF-kB Signaling
|
|
Fibronectin Expression Targets
|
|
CTGF -> AP-1/CREB/MYC Expression Targets
|
|
CTGF -> FOXO3A Expression Target
|
|
CTGF -> NCOR2 Expression Target
|
|
ICAM1 Expression Targets
|
|
Fibrinogen Expression Targets
|
|
IL7R -> FOXO/NF-kB Signaling
|
|
IL15R -> NF-kB/NFATC Signaling
|
|
IL2R -> ELK/SRF/MYC Signaling
|
|
IL23R -> STAT3/NF-kB Signaling
|
|
IL12R -> NF-kB/NFATC Signaling
|
|
IL4R -> ELK/SRF/HMGY Signaling
|
|
IL7 Expression Targets
|
|
IL15 Expression Targets
|
|
IL12B Expression Targets
|
|
IL4 Expression Targets
|
|
IL2 Expression Targets
|
|
UrokinaseR -> ELK/SRF Signaling
|
|
LPA Expression Targets
|
|
PAF/Gq -> AP-1/ATF1/CREB/ERK/SRF Expression Targets
|
|
Dronabinol/Anandamide Expression Targets
|
|
PAF/Gq -> NF-kB Expression Targets
|
|
GPCRs Family -> Expression Targets in Lymphoid System and Blood
|
|
NRG1 -> MEF/MYOD Expression Targets
|
|
NRG1 -> EP300/ETS/ETV/SP1 Expression Targets
|
|
NRG1 -> CREB/CREBBP/ELK/SRF/MYC Expression Targets
|
|
NRG1 -> FOXO3A Expression Targets
|
|
NRG1 -> TP53 Expression Target
|
|
NRG1 -> AP-1/ATF Expression Targets
|
|
NRG1 -> HIF1A Expression Target
|
|
NGF -> SMAD3/NF-kB Expression Targets
|
|
NGF -> AP-1/TP53/MYC Expression Targets
|
|
NGF -> FOXO/MYCN/ELK-SRF Expression Targets
|
|
BDNF Expression Targets
|
|
NTF3 Expression Targets
|
|
NTF4 Expression Targets
|
|
NGF -> CREB/CEBPB/MEF2A Expression Targets
|
|
NOTCH -> NF-kB Signaling
|
|
DLL4 Expression Targets
|
|
ADAM17 Expression Targets
|
|
JAG1 Expression Targets
|
|
DLL1 Expression Targets
|
|
NOTCH Expression Targets
|
|
Adenosine Expression Targets
|
|
PDGFB -> AP-1/CREB/MYC Expression Target
|
|
PDGFB -> FOXO3A Expression Target
|
|
PDGFC -> CREB Expression Target
|
|
PDGFD -> AP-1 Expression Targets
|
|
PDGF -> AP-1/CREB/CREBBP/MYC Expression Targets
|
|
PDGF -> FOXO3A Expression Targets
|
|
KIT -> MITF Signaling
|
|
PDGFR -> AP-1/MYC Signaling
|
|
PDGFR -> FOXO3A Signaling
|
|
AVP/Gs -> CREB/ELK/SRF/AP-1/EGR Expression Targets
|
|
NTS Expression Targets
|
|
AVP/Gs -> MEF/MYOD/NFATC/MYOG Expression Targets
|
|
NPY Expression Targets
|
|
AVP/Gq -> MEF/MYOD/NFATC/MYOG Expression Targets
|
|
AVP/Gq -> CREB/ELK/SRF/AP-1/EGR Expression Targets
|
|
PRL/GHR -> NF/kB/ELK/SRF/MYC Expression Targets
|
|
GUCYC2 Signaling
|
|
AngiopoietinR -> AP-1 Signaling
|
|
AngiopoietinR -> FOXO Signaling
|
|
GDNF -> HSF1 Signaling
|
|
EphrinB -> MAPK/JUN/FOS Signaling
|
|
NTRK -> FOXO/MYCN Signaling
|
|
NTRK -> AP-1/CREB/ELK/SRF/MYC/SMAD3/TP53 Signaling
|
|
GAS6 -> AP-1/CREB Expression Targets
|
|
FIGF -> AP-1 Expression Target
|
|
FIGF -> NCOR2 Expression Target
|
|
KITLG -> AP-1/CREB/CREBBP/MYC Expression Targets
|
|
CSF1 -> FOXO3A Expression Targets
|
|
GDNF -> HSF1 Expression Targets
|
|
CSF1 -> AP-1/CREB/CREBBP/MYC Expression Targets
|
|
PGF -> AP-1/CREB/CREBBP/MYC Expression Targets
|
|
Elevated Receptors -> Expression Targets in Respiratory System
|
|
Lysophosphatidic Acid/LPARs Signaling
|
|
FOXO1 Signaling
|
|
MERTK Signaling
|
|
Ras Signaling
|
|
TGF-beta Signaling
|
|
AXL Receptor Tyrosine Kinase Signaling
|
|
PI3K/RAC1 Signaling
|
|
mTOR Signaling
|
|
TNF-alpha/TNFRSF1B Signaling
|
|
KRAS Signaling
|
|
VEGF Signaling
|
|
Estrogens/ESR1 non-Genomic Signaling
|
|
EGFR Signaling
|
|
HRAS Signaling
|
|
Hedgehog Family Signaling
|
|
T-Cell Receptor -> NF-kB Signaling
|
|
TGFA -> FOXO3A Expression Targets
|
|
TGFA -> TP53 Expression Targets
|
|
TGFA -> HIF1A Expression Targets
|
|
TGFA -> MEF/MYOD/NFATC Expression Targets
|
|
TGFA/AP-1/ATF Expression Targets
|
|
TGFA -> CREB/CREBBP/ELK-SRF/MYC Expression Targets
|
|
CD40LG -> NF-kB/ELK/SRF -> CREB/NFATC Expression Targets
|
|
TNFSF13B Expression Targets
|
|
TNFRSF5/13B -> NFATC1 Signaling
|
|
Thrombopoietin -> SPI1 Expression Targets
|
|
Thrombopoietin -> AP-1/CREB/CREBBP/MYC Expression Targets
|
|
Thrombopoietin -> FOXO3A Expression Target
|
|
TLR1 -> 2/6 Expression Targets
|
|
TLR1/2/6 -> NF-kB Signaling
|
|
Glutamate Mediated Neurotoxicity
|
|
Ca2+ Cytosolic Overload
|
|
ROS in Angiotensin Mediated Cardiovascular Remodeling and Hypertrophy
|
|
PLAU -> ELK-SRF/AP-1 Expression Targets
|
|
VEGFC -> CTNNB Expression Target
|
|
VEGFA -> FOXO3A Expression Targets
|
|
VEGFA -> AP-1/CREBBP/MYC Expression Targets
|
|
VEGFA -> CTNNB/CTNND Expression Targets
|
|
VEGFA -> NCOR2 Expression Target
|
|
VEGFR -> CTNNB Signaling
|
|
VEGFR -> AP-1/CREB/MYC Signaling
|
|
VEGFR -> FOXO3A Signaling
|
|
n
|
|
Model of PPARG signaling in psoriasis
|
|
Model of PPARG related pathways in psoriasis (short version)
|
|
3_Increased proliferation of sebocytes in acne vulgaris
|
|
2_Interleukin-17 and interleukin-22 signaling in psoriasis
|
|
1_The onset of atopic dermatitis
|
|
2_Osteoblast-mediated bone demineralization
|
|
1_Formation of cysts in polycystic kidney disease
|
|
3_Mesangial cell dysfunction in glomerulonephritis
|
|
1_Local estrogen production stimulates ectopic endometrium proliferation
|
|
3_Enhanced angiogenesis in endometriosis
|
|
2_Impaired steroidogenesis in PCOS
|
|
3_Role of neurotrophic factor deprivation in retinal ganglion cell death
|
|
2_Pathogens stimulate mucins expression in the middle ear
|
|
3_Arterial wall inflammation and calcification in atherosclerosis
|
|
4_Endothelial cells repress vasoconstriction in hypertension
|
|
2_The intense proliferation and contractile activity of smooth muscle cells in pulmonary hypertension
|
|
1_Cigarette smoke causes dysfunction and production of inflammatory mediators in alveolar epithelial cells
|
|
3_Role of alveolar macrophages in pulmonary tissue destruction in COPD
|
|
1_Th2 cell response in asthma
|
|
3_1_Mucus accumulation in asthma
|
|
2_2_Eosinophilia and neutrophilia in asthma: eosinophil apoptosis
|
|
4_2_Airway smooth muscle cells proliferation and airway tissue remodeling
|
|
4_Mucin hyperproduction in goblet and mucous cells in COPD
|
|
2_Intestine epithelial cells drive immunological responses in ulcerative colitis
|
|
1_Triglyceride storage in NAFLD
|
|
1_CD4+ T cell and epithelial cell response in celiac disease
|
|
4_Tax-induced disruption of the G1/S transition in HTLV-1 infected T-cell
|
|
2_HIV - induced depletion of CD4+ T-cells
|
|
3_1_Beta-cell proliferation and compensation: proliferation
|
|
1_1_Insulin synthesis and secretion: insulin processing and storage
|
|
3_3_Beta-cell proliferation and compensation: recovery
|
|
4_1_Insulin resistance: insulin signaling
|
|
1_Antigen-presenting cells promote islet dysfunction and immune system activation in T1D
|
|
1_Microangiopathy in diabetic neuropathy
|
|
2_Neuron and Schwann cell death
|
|
1_Glutamate and calcium excitotoxicity of motor neurons in ALS
|
|
1_1_Glutamate overload enforced prostaglandins and NO synthesis in neurons
|
|
2_1_General pathways of thyroid hormone signaling
|
|
Model of PPARG signaling in psoriais (tested)
|
|
DIPG non histone mutations
|
|
DIPG overview_2
|
|
HRAS->RAF->MAPK1/3
|
|
Interleukin-17 and interleukin-22 signaling in psoriasis
|